Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. VALBIOTIS
  6. News
  7. Summary
    ALVAL   FR0013254851

VALBIOTIS

(ALVAL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

VALBIOTIS : Rapport financier semestriel 2021

09/30/2021 | 01:52am EST
Rapport financier semestriel 2021
Subscribe

30 Sep 2021 07:38 CEST

Company Name

VALBIOTIS

ISN

FR0013254851

Market

Euronext Growth

Symbol

ALVAL

Source

VALBIOTIS

Provider

Euronext

Disclaimer

Valbiotis SA published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2021 05:51:06 UTC.


ę Publicnow 2021
All news about VALBIOTIS
12/01GLOBAL MARKETS LIVE : Merck, Volkswagen, Salesforce, Roche, Mondelez...
12/01Valbiotis Submits to the Competent Authorities the Three Clinical Protocols for TOTUM?8..
CI
11/15Valbiotis Announces Positive Preclinical Results for TOTUM?070 in Hypercholesterolemia,..
CI
09/30VALBIOTIS : Rapport financier semestriel 2021
PU
09/30VALBIOTIS : Publication of 2021 half-year results
PU
09/30Valbiotis Reports Earnings Results for the First Half 2021
CI
09/24VALBIOTIS : Enters Joint Research Project on Natural Health
MT
09/24MICROALGAE : exclusive agreement with IFREMER and ADECAL Technopole
PU
09/24Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integr..
CI
09/09VALBIOTIS : Release of Letter to Shareholders for 2021
PU
More news
Financials
Sales 2021 3,75 M 4,25 M 4,25 M
Net income 2021 -5,45 M -6,17 M -6,17 M
Net cash 2021 17,3 M 19,6 M 19,6 M
P/E ratio 2021 -8,94x
Yield 2021 -
Capitalization 66,5 M 75,1 M 75,3 M
EV / Sales 2021 13,1x
EV / Sales 2022 3,70x
Nbr of Employees 35
Free-Float 89,1%
Chart VALBIOTIS
Duration : Period :
VALBIOTIS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VALBIOTIS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 6,84 €
Average target price 14,33 €
Spread / Average Target 110%
EPS Revisions
Managers and Directors
Sebastien M. Peltier Chairman & Chief Executive Officer
Jocelyn Pineau Chief Financial Officer
Laurent LÚvy Chairman-Supervisory Board
Pascal Sirvent Chief Scientific Officer
Murielle Cazaubiel Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VALBIOTIS12.87%73
GILEAD SCIENCES, INC.19.58%87 393
BIONTECH SE310.30%80 545
REGENERON PHARMACEUTICALS31.23%66 288
WUXI APPTEC CO., LTD.26.31%65 499
VERTEX PHARMACEUTICALS-13.49%51 982